Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3391068 | Seminarios de la Fundación Española de Reumatología | 2012 | 8 Pages |
Abstract
Prompt recognition of the disease and early initiation of therapy can prevent loss of vision in the affected eye or new visual deficits in the contralateral eye. The treatment of GCA is based on daily glucocorticoid administration, which should be started urgently in patients with incipient visual symptoms (diplopia or amaurosis fugax). The duration of glucocorticoid therapy is unpredictable and adverse effects are common. The aim of treatment is mainly to prevent the progression of visual loss.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Ángeles Acosta-Mérida, Félix M. Francisco Hernández,